Physician profile
Lorna M Barte
NPI 1154376762
$25,221.24
in general payments reported to CMS, 2019-2025
30 companies · $6,386 in 2025
The $6,386 reported for 2025 was more than what 95% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,209 · 2020: $1,673 · 2021: $3,783 · 2022: $3,939 · 2023: $3,501 · 2024: $4,730 · 2025: $6,386.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Education: $94.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,523.16 |
| Education | $94.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $4,182.43 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Neurocrine Biosciences, INC. | $3,021.30 | 2019-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,831.79 | 2020-2025 | Caplyta |
| Abbvie INC. | $2,693.58 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Teva Pharmaceuticals USA, INC. | $1,775.76 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Vanda Pharmaceuticals INC. | $1,728.35 | 2019-2025 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $1,330.39 | 2019-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $1,173.53 | 2020-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Alkermes, INC. | $947.07 | 2019-2025 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $635.96 | 2022-2025 | Auvelity |
| Indivior INC. | $549.24 | 2019-2024 | Perseris |
| Allergan, INC. | $512.32 | 2019-2020 | |
| Almatica Pharma LLC | $464.05 | 2021-2025 | Loreev Xr, Sertraline Hcl, Gralise |
| E.R. Squibb & Sons, L.L.C. | $456.33 | 2024-2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $403.94 | 2020-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Azurity Pharmaceuticals, INC. | $319.03 | 2023-2025 | Horizant, Horizant, Alvesco |
| Bausch Health US, LLC | $313.59 | 2020-2025 | Aplenzin, Wellbutrin |
| Avanir Pharmaceuticals, INC. | $281.01 | 2019-2021 | |
| Corium, LLC | $259.93 | 2022-2024 | Azstarys |
| Janssen Pharmaceuticals, INC | $227.87 | 2019-2024 | Spravato |
| Sage Therapeutics, LLC | $220.65 | 2024-2025 | Zurzuvae |
| Eisai INC. | $209.67 | 2020-2022 | |
| Idorsia Pharmaceuticals US INC | $195.12 | 2023-2025 | Quviviq, Quviviq |
| Merck Sharp & Dohme LLC | $172.12 | 2020-2023 | Belsomra |
| Arbor Pharmaceuticals, INC. | $94.06 | 2020-2022 | |
| Noven Therapeutics, LLC | $85.54 | 2024 | Secuado, Xelstrym |
| Jazz Pharmaceuticals INC. | $57.87 | 2021 | |
| Supernus Pharmaceuticals, INC. | $39.39 | 2025 | Qelbree |
| Ironshore Pharmaceuticals INC. | $23.96 | 2019 | |
| Tonix Medicines, INC. | $15.39 | 2025 | Tonmya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lorna Barte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.